Return to Listing

1 result(s) for Dovitinib

PI Name Protocol # Title
Matthew Taylor IRB00010653 Module Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080

You may qualify for additional trials within our Phase 1 Program